SCOTTSDALE, Ariz., June 17 /PRNewswire/ -- MedPredict has published a new report designed to provide critical strategic insight for pharma and biotech companies with a stake in the market for diagnostics and treatments in this disease area. The report, entitled "Thought Leader Insight & Analysis: Alzheimer's Disease," is based on in-depth interviews conducted with a panel of physician thought leaders actively involved in ongoing research.
"There is some real progress being made in development of diagnostics and treatments for Alzheimer's disease," said Dr. Jeffrey Berk, the primary author of this report. "Today's announcement by Wyeth and Elan revealing clinically meaningful results in their Phase II trial of bapineuzumab underscores that progress. Our Thought Leader Panel is excited about the potential for bapineuzumab, and this report provides their interpretation of the trial results and how they might impact ongoing research."
Each panelist offers his perspective on those agents and mechanisms that have the strongest data supporting them, and comments on those where the excitement extends beyond the clinical evidence. These include ARBs, acetylcholinesterase (butyrylcholinesterase) inhibitors, NMDA, M1, 5-HT, alpha-7 nicotinic acetylcholine agonists, active and passive immunotherapy, gamma-secretase and beta-secretase inhibitors, insulin related mechanisms (IDE, RAGE), anti-TNF and more.
With regard to diagnostics, "We expect demand for diagnostics is going to skyrocket in concert with approvals of agents that alter the course of the disease," continued Dr. Berk. "Our panelists are most excited about amyloid imaging using a tracer chemical called PIB."
Companies mentioned in this report: GE Healthcare, Avid, Bayer Schering, Siemens, C2N Diagnostics, Satoris, Novartis, Forest, Merz, Lundbeck, Daiichi Sankyo, Medivation, Abbott, AstraZeneca, Targacept, Roche, Memory, EnVivo, Wyeth, Epix, GlaxoSmithKline, Merck, Takeda, Sanofi-Aventis, Bristol Myers Squibb, Boehringer Ingelheim, Baxter, Lilly, Intellect Neurosciences, Elan, Myriad, AC Immune, Genentech, Affiris, TransTec, Pfizer, TorreyPines, Transition Therapeutics, Neurochem.
The full report can be purchased by contacting MedPredict at http://www.medpredict.com.
MedPredict (http://www.medpredict.com) maintains a proprietary database of over 1,000 global physician thought leaders, including 40+ specialties in 30+ therapeutic categories. Based on primary interviews with these thought leaders, MedPredict publishes periodic reports in each category to keep clients up-to-date on emerging trends and competitive activity. The reports include thought leader reactions to recent publications and medical conferences, as well as clinical, regulatory and marketing activity.
Copyright©2008 PR Newswire.
All rights reserved